Tekmira Pharmaceuticals (TKMR)
Tekmira Pharmaceuticals Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TKMR Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4260 |
| Sector | 99th percentile | 1 of 478 in Healthcare |
| Industry | 94th percentile | 1 of 17 in Diagnostic Substances |
TKMR Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Sep 2007 |
| Maximum | 0.0001 | Jun 2007 |
| Average | 0.0000 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these TKMR related companies
TKMR News
From Earlier: Tekmira Provides Periodic Update to Shareholders Regarding Litigation
May 25, 7:05AM Benzinga
May 25, 7:05AM Benzinga
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
May 15, 4:00PM GlobeNewswire
May 15, 4:00PM GlobeNewswire
$TKMR forms bearish "Top Triangle" chart pattern. http://stks.co/3mUC
about 22 days ago by RecogniaEvents
about 22 days ago by RecogniaEvents
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
May 09, 4:47PM GlobeNewswire
May 09, 4:47PM GlobeNewswire
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
Apr 20, 10:51AM GlobeNewswire
Apr 20, 10:51AM GlobeNewswire
Tekmira (TKMR) Narrows FY11 Loss on Lighter Sales; Sees Flat FY12 Revs
Mar 27, 4:12PM Street Insider
Mar 27, 4:12PM Street Insider
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
Mar 22, 4:40PM GlobeNewswire
Mar 22, 4:40PM GlobeNewswire
From Earlier: Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
Mar 15, 7:13AM Benzinga
Mar 15, 7:13AM Benzinga
Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
Mar 15, 12:50AM GlobeNewswire
Mar 15, 12:50AM GlobeNewswire
Breakout candidate: $ARWR http://stks.co/2l0W Other RNAi companies: $ALNY $TKMR
about 85 days ago by Xatta_Trading
about 85 days ago by Xatta_Trading
$TKMR forms bearish "Continuation Wedge" chart pattern. http://stks.co/2haW
about 87 days ago by RecogniaEvents
about 87 days ago by RecogniaEvents
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
Mar 01, 8:00AM GlobeNewswire
Mar 01, 8:00AM GlobeNewswire
Tekmira Updates Financial Guidance: Cash Runway Further Extended Into Second Half of 2013
Feb 29, 11:57PM GlobeNewswire
Feb 29, 11:57PM GlobeNewswire
Tekmira Provides Periodic Update to Litigation; Alnylam Pharma Files Suit Against Tekmira
Jan 17, 4:33PM Benzinga
Jan 17, 4:33PM Benzinga
Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
Nov 28, 8:00AM GlobeNewswire
Nov 28, 8:00AM GlobeNewswire
Tekmira files for an injunction in the Supreme Court of British Columbia
Nov 16, 8:37AM FlyOnTheWall
Nov 16, 8:37AM FlyOnTheWall
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
Nov 08, 4:00PM GlobeNewswire
Nov 08, 4:00PM GlobeNewswire
Tekmira Conference Call and Webcast Advisory: Third Quarter 2011 Operating Results and Corporate Update
Nov 03, 4:30PM GlobeNewswire
Nov 03, 4:30PM GlobeNewswire
Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
Sep 12, 8:06AM Benzinga
Sep 12, 8:06AM Benzinga
Tekmira Pharmaceuticals (TKMR) Acquires Worldwide Exclusive License to Novel RNAi Platform
Aug 25, 8:21AM Street Insider
Aug 25, 8:21AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TKMR | 1.95 | -0.20 | -9.27% | 30.09M |
| TKF | 12.07 | -0.13 | -1.07% | |
| TKC | 11.09 | +0.26 | +2.40% | 9.530B |
| TK | 26.16 | -0.78 | -2.90% | 1.856B |
| TJX | 40.90 | -1.56 | -3.67% | 31.70B |
| TIVO | 8.07 | -0.47 | -5.50% | 1.044B |
| TD | 73.85 | -2.52 | -3.30% | 68.96B |
| TCX | 1.33 | -0.07 | -5.00% | 64.67M |
| TCRD | 12.33 | -0.35 | -2.76% | 256.39M |
| TCP | 40.78 | -0.22 | -0.54% | 2.192B |
